Oxford Biomedica’s (OXB) Outperform Rating Reiterated at Royal Bank Of Canada

Oxford Biomedica (LON:OXB – Get Free Report)‘s stock had its “outperform” rating reissued by Royal Bank Of Canada in a research note issued on Tuesday, Digital Look reports. They presently have a GBX 900 price target on the biopharmaceutical company’s stock. Royal Bank Of Canada’s target price indicates a potential upside of 106.66% from the company’s previous close.

OXB has been the topic of a number of other reports. Deutsche Bank Aktiengesellschaft restated a “hold” rating and issued a GBX 595 price objective on shares of Oxford Biomedica in a research note on Wednesday. Jefferies Financial Group reissued a “buy” rating and set a GBX 8.27 price target on shares of Oxford Biomedica in a report on Tuesday, June 2nd. Four analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of GBX 580.85.

Get Oxford Biomedica alerts:

View Our Latest Stock Analysis on OXB

Oxford Biomedica Stock Down 2.6%

OXB stock opened at GBX 435.49 on Tuesday. The company has a market cap of £527.10 million, a price-to-earnings ratio of -16.18 and a beta of 1.10. The company has a fifty day moving average price of GBX 566.92 and a 200 day moving average price of GBX 606.44. The company has a debt-to-equity ratio of 162.16, a current ratio of 2.20 and a quick ratio of 1.67. Oxford Biomedica has a 12 month low of GBX 427 and a 12 month high of GBX 952.

About Oxford Biomedica

(Get Free Report)

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.

See Also

• Five stocks we like better than Oxford Biomedica
• Dutch Bros Sell-Off Creates a Growth Opportunity
• NVIDIA’s MediaTek Bet Shows How It Plans to Defend Its AI Moat
• Is Abercrombie & Fitch’s Hot Streak Just Getting Started?
• Medtronic’s Stars Are Aligning for a Price Recovery

Receive News & Ratings for Oxford Biomedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Biomedica and related companies with MarketBeat.com's FREE daily email newsletter.